for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

84.34USD

Change

0.58(+0.69%)

Volume

2,134,615

Today's Range

84.27

 - 

85.44

52 Week Range

66.10

 - 

87.35

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
83.76
Open
84.38
Volume
2,134,615
3M AVG Volume
180.70
Today's High
85.44
Today's Low
84.27
52 Week High
87.35
52 Week Low
66.10
Shares Out (MIL)
2,560.37
Market Cap (MIL)
215,942.00
Forward P/E
17.12
Dividend (Yield %)
2.61

Next Event

Q3 2019 Merck & Co Inc Earnings Call

Latest Developments

More

4D Pharma Collaborates With MSD To Develop Live Biotherapeutics For Vaccines

Merck’s Keytruda Now Approved As Monotherapy In China

FDA Accepts 2 Applications For Merck's DIFICID (Fidaxomicin) To Treat Children Aged 6 Months To 18 Years With Clostridium Difficile Infections

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Jim Scholefield

Executive Vice President, Chief Information and Digital Officer

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Key Stats

1.71 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

39.8K

2017

40.1K

2018

42.3K

2019(E)

45.9K
EPS (USD)

2016

3.780

2017

3.980

2018

4.340

2019(E)

4.918
Price To Earnings (TTM)
22.74
Price To Sales (TTM)
4.87
Price To Book (MRQ)
7.83
Price To Cash Flow (TTM)
15.85
Total Debt To Equity (MRQ)
96.21
LT Debt To Equity (MRQ)
82.40
Return on Investment (TTM)
14.71
Return on Equity (TTM)
11.36

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up